Skip to main content
Premium Trial:

Request an Annual Quote

Sarah Cannon, Syapse Collaborate to Expand Genomic Profiling Efforts

NEW YORK (GenomeWeb) – Cancer services and research network Sarah Cannon and Syapse today announced a collaboration to launch a software-based service in support of Sarah Cannon's tumor genome profiling efforts. 

The service, expected to launch in the second half of 2015, will provide Sarah Cannon's network of cancer centers access to genomic testing, best practices guidelines, and decision support. It also will allow Sarah Cannon to streamline genomic data analysis in order to improve patient outcomes and expand clinical trial options for patients, the partners said. 

The service, they added, supports Sarah Cannon's efforts to expand genomic profiling to its more than 100,000 newly diagnosed cancer patients seen annually in the US and the UK.  

Sarah Cannon is the global cancer enterprise of Hospital Corporation of America and offers clinical research and integrated cancer services. 

"Our research, care, and drug development initiatives to advance precision medicine in cancer are further enhanced through the use of the Syapse software platform," Sarah Cannon President of Clinical Operations Howard Burris III said in a statement. "Combining clinical history, treatments, genomics, outcomes, and other relevant data within one system will help our physicians and researchers more rapidly identify patterns in patient data that support the development of personalized treatment plans for patients."